We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

RHODOS Follow-up Single-visit Study (RHODOS-OFU)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01421381
First Posted: August 22, 2011
Last Update Posted: May 27, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Santhera Pharmaceuticals
August 19, 2011
August 22, 2011
May 27, 2013
September 2011
November 2011   (Final data collection date for primary outcome measure)
logMAR visual acuity [ Time Frame: measure taken at the single study visit (Week 24) ]
Change in best logMAR visual acuity (Best Acuity) compared to Visit 2/Baseline and Visit 5/Week 24 or last treatment visit of SNT-II-003
Same as current
Complete list of historical versions of study NCT01421381 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
RHODOS Follow-up Single-visit Study
A Single Visit, Observational, Follow-up Study of Patients With Leber's Hereditary Optic Neuropathy Following Participation in SNT-II-003 Trial
This study aims to evaluate the current visual acuity of SNT-II-003 participants and compare this with the last visit from the SNT-II-003 study.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients who participated in study SNT-II-003
Leber's Hereditary Optic Neuropathy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
December 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previous participation in study SNT-II-003
Sexes Eligible for Study: All
15 Years to 69 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Germany,   United Kingdom
 
 
NCT01421381
SNT-II-003-OFU
Not Provided
Not Provided
Not Provided
Santhera Pharmaceuticals
Santhera Pharmaceuticals
Not Provided
Principal Investigator: Patrick Chinnery, MD Clinical Research Facility
Santhera Pharmaceuticals
May 2013